🏷

Classifications

Harrison's Chapter

ICD-O Morphology

◆

Subtypes

2

Classic (Typical) Seminoma

>90% of pure seminomas

Classic seminoma is the prototypical and by far most common form, accounting for the great majority of pure seminomas. It arises from GCNIS, occurs predominantly in men aged 15-44 with a peak around 35-39 years, and presents most often as clinical stage I disease. Histologically it shows sheets and nests of uniform polygonal cells with clear, glycogen-rich cytoplasm and central nuclei, separated by fibrous septa containing a characteristic lymphocytic infiltrate. It is GCNIS-derived, harbors i(12p), expresses the primordial-germ-cell/pluripotency program (OCT4, SOX17, NANOG, TFAP2C), and is highly radio- and chemosensitive.

Show evidence (1 reference)

DOI:10.1038/s41467-023-44305-9 SUPPORT Human Clinical

"Seminoma is the most common malignant solid tumor in 14 to 44 year-old men"

Establishes classic seminoma as the most common solid malignancy in this age range.

Spermatocytic Tumor (formerly Spermatocytic Seminoma)

<1% of testicular germ cell tumors

Spermatocytic tumor is a rare, biologically distinct germ cell tumor that, despite the historical name, is NOT a variant of classic seminoma. It occurs almost exclusively in older men (typically >50 years), arises independently of GCNIS, lacks isochromosome 12p and the OCT4/pluripotency program, shows three cell populations (small, intermediate, large) without lymphocytic infiltrate, and is almost always benign with rare metastasis. It is included here only to make the lump/split decision explicit: it is split from the classic seminoma concept and is not managed with the seminoma radiotherapy/chemotherapy paradigm. Curated as a contrasting subtype rather than as a true sub-form of classic seminoma.

⚙

Pathophysiology

5

Germ Cell Neoplasia In Situ (GCNIS)

Classic seminoma arises from germ cell neoplasia in situ (GCNIS), a preinvasive lesion composed of transformed fetal gonocytes/primordial germ cells that failed to mature and remained dormant within the seminiferous tubules until pubertal hormonal stimulation. Unlike most cancers, TGCTs including seminoma are rarely driven by somatic point mutations; instead they reflect a failure to control the latent developmental potential of their fetal germ-cell-of-origin, with reprogramming toward a malignant primordial germ cell-like state.

primordial germ cell CL:0000670

germ cell development GO:0007281 ⚠ ABNORMAL

seminiferous tubule UBERON:0001343

Downstream

Isochromosome 12p and Copy-Number-Driven Genome GCNIS progresses to invasive seminoma after acquiring chromosome 12p gain and additional copy-number alterations.

Show evidence (2 references)

DOI:10.1038/s41467-024-53193-6 SUPPORT Human Clinical

"our findings provide valuable insights into the developmental and immune modulatory processes implicated in TGCT pathogenesis and progression"

WGS of adult TGCTs frames seminoma pathogenesis as a developmental/immune-modulatory process arising from the fetal germ cell lineage.

DOI:10.1038/s41467-023-44305-9 SUPPORT Human Clinical

"We identify key gene expression programs share between seminoma and primordial germ cells, and further characterize the functions of TFAP2C in promoting tumor invasion and migration"

Single-cell multi-omics confirms the shared primordial germ cell program of seminoma and identifies TFAP2C as a driver of invasion, consistent with a GCNIS/gonocyte origin.

Isochromosome 12p and Copy-Number-Driven Genome

Seminoma genomes are dominated by chromosomal copy-number change rather than recurrent somatic point mutations. Gain of the short arm of chromosome 12 - most often as isochromosome 12p [i(12p)] - is the hallmark cytogenetic event, and whole-genome sequencing of adult TGCTs identifies recurrent arm-level gains spanning KRAS on 12p. The 12p region harbors KRAS, CCND2, and NANOG, supporting pluripotency and proliferation.

cell population proliferation GO:0008283 ↑ INCREASED chromosome organization GO:0051276 ⚠ ABNORMAL

Downstream

KIT and RAS-MAPK Signaling Activation 12p-amplified KRAS and recurrent KIT amplification converge on RAS-MAPK signaling.

Show evidence (1 reference)

DOI:10.3389/fonc.2023.1133363 SUPPORT Human Clinical

"KRAS copy number gain was a very frequent event (80.4%) in TGCT and presented a worse prognosis compared with the group with no KRAS copy gain (10y-OS, 90% vs. 81.5%, p = 0.048)"

Demonstrates the high frequency and prognostic relevance of KRAS (12p) copy-number gain in TGCT, consistent with i(12p) biology.

KIT and RAS-MAPK Signaling Activation

Activating alterations of KIT and KRAS are the principal recurrent driver events in seminoma. WGS of adult TGCTs identified focal KIT amplification in approximately 19% of cases, and KIT mutations are enriched in seminoma relative to non-seminoma. KIT (a receptor tyrosine kinase) and amplified/mutated KRAS activate the RAS-RAF-MEK-ERK (MAPK) cascade, driving germ cell survival and proliferation.

MAPK cascade GO:0000165 ↑ INCREASED

Downstream

Platinum and Radiation Sensitivity KIT/RAS-MAPK-driven proliferation underlies the high mitotic activity and limited DNA damage tolerance of seminoma cells, which is precisely what cisplatin-based chemotherapy and radiotherapy exploit to achieve the characteristically high cure rates.

Show evidence (2 references)

DOI:10.1038/s41467-024-53193-6 SUPPORT Human Clinical

"Testicular germ cell tumours (TGCT), which comprise seminoma and non-seminoma subtypes, are the most common cancers in young men"

Anchors the WGS catalogue (which reports recurrent KIT amplification and 12p/KRAS gains) to seminoma and non-seminoma TGCT subtypes.

DOI:10.3389/fonc.2023.1133363 SUPPORT Human Clinical

"Variants were also detected in genes such as KIT, KRAS, PDGFRA, EGFR, BRAF, RET, NRAS, PIK3CA, MET, and ERBB2, with some of them potentially targetable"

Confirms recurrent KIT and KRAS variants among the actionable driver genes in TGCT.

Immune-Infiltrated Microenvironment and HLA-Loss Immune Evasion

Seminoma is characteristically heavily infiltrated by immune cells, with a shift from the macrophage-dominated normal testis toward a T-cell-, B-cell-, and dendritic-cell-rich microenvironment. CD4+ T cells predominate over CD8+ cells, and regulatory T (Treg) and follicular helper T (Tfh) cells are most abundant in seminoma. Single-cell/spatial studies localize immune subtypes with exhaustion features adjacent to the tumor. Whole-genome sequencing identifies human leukocyte antigen (HLA) loss as a seminoma-enriched mechanism of immune disruption, providing a route to immune evasion despite robust infiltration.

CD4-positive T cell CL:0000624 regulatory T cell CL:0000815 macrophage CL:0000235

T cell activation GO:0042110 ↑ INCREASED antigen presentation via MHC class I GO:0002474 ↓ DECREASED

Show evidence (4 references)

DOI:10.1038/s41416-024-02669-9 SUPPORT Human Clinical

"In most samples (96%), the CD4+ T cell frequency exceeded that of CD8+ cells, with decreasing numbers from central to peripheral tumor areas, and to tumor-free, contralateral testes. T cells including Treg and Tfh were most abundant in seminoma compared to mixed tumors and embryonal carcinoma"

Documents the CD4-predominant infiltrate and seminoma enrichment of Treg/Tfh subsets.

DOI:10.1038/s41467-024-53193-6 SUPPORT Human Clinical

"we present evidence that human leukocyte antigen loss is a more prevalent mechanism of immune disruption in seminomas"

WGS identifies HLA loss as a seminoma-enriched immune-evasion mechanism.

DOI:10.1038/s41467-023-44305-9 SUPPORT Human Clinical

"We also identify 15 immune cell subtypes in TME, and find that subtypes with exhaustion features were located closer to the tumor region through combined spatial transcriptome analysis"

Spatial multi-omics shows exhaustion-featured immune subtypes localizing to the seminoma tumor region.

+ 1 more reference

Platinum and Radiation Sensitivity

Seminoma is exquisitely sensitive to both ionizing radiation and platinum-based chemotherapy. As with TGCTs broadly, this sensitivity reflects limited DNA repair capacity - notably reduced ERCC1-XPF that impairs repair of cisplatin interstrand crosslinks - combined with a strong propensity to undergo apoptosis. Because TGCTs including seminoma almost universally retain wild-type TP53, DNA-damaging therapy drives a robust p53-controlled apoptotic response through both the intrinsic mitochondrial pathway (high endogenous Bax and Noxa with low Bcl-2, Bax translocation to the mitochondrial membrane and cytochrome c release) and the extrinsic Fas/FasL death-receptor pathway, so that DNA-damaging therapy efficiently triggers tumor cell death. This underlies cure rates approaching 99% in early-stage and over 80% in advanced disease.

apoptotic process GO:0006915 ↑ INCREASED extrinsic apoptotic signaling via Fas/FasL GO:0008625 ↑ INCREASED intrinsic (mitochondrial) apoptotic signaling GO:0097193 ↑ INCREASED nucleotide-excision repair GO:0006289 ↓ DECREASED

Show evidence (4 references)

PMID:37891379 SUPPORT In Vitro

"metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients using cisplatin-based combination therapy. Published data suggest that TGCTs are sensitive to cisplatin due to limited DNA repair and presumably also to a propensity to undergo apoptosis"

Establishes the dual basis (limited DNA repair plus apoptotic propensity) for the platinum sensitivity that seminoma shares with TGCTs.

PMID:37891379 SUPPORT In Vitro

"both the death receptor and the mitochondrial apoptotic pathway become strongly activated in TTC following cisplatin treatment, explaining, together with attenuated DNA repair, their unique sensitivity toward platinum-based anticancer drugs"

In testis tumor cell lines, cisplatin activates both the extrinsic Fas/FasL death-receptor and the intrinsic mitochondrial apoptotic pathways, which together with attenuated DNA repair account for the exceptional platinum sensitivity.

PMID:37891379 SUPPORT In Vitro

"Almost all TGCT are characterized by wild-type p53"

Near-universal retention of wild-type TP53 is the basis for the intact p53-driven apoptotic response that renders seminoma and other TGCTs platinum-sensitive.

+ 1 more reference

✶

Histopathology

2

Uniform Clear Cells in Sheets and Nests VERY_FREQUENT

Sheets and nests of monotonous polygonal cells with abundant clear, glycogen-rich cytoplasm, distinct cell membranes, and central nuclei with prominent nucleoli, separated by delicate fibrous septa. Classic diagnostic morphology of seminoma.

Lymphocytic Infiltrate in Fibrous Septa FREQUENT

A characteristic lymphocytic (predominantly T-cell) infiltrate within the fibrous septa is a hallmark of seminoma and reflects its immune-infiltrated microenvironment; a granulomatous reaction may also be seen.

Show evidence (1 reference)

DOI:10.1038/s41416-024-02669-9 SUPPORT Human Clinical

"Immune cell infiltration is heterogeneous but common in testicular germ cell tumors (TGCT) and pre-invasive germ cell neoplasia in situ (GCNIS)"

Supports the common immune-cell infiltration that manifests histologically as the seminoma lymphocytic infiltrate.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Genitourinary 2

Testicular Mass Testicular neoplasm HP:0010788

Show evidence (1 reference)

DOI:10.1038/s41467-023-44305-9 SUPPORT Human Clinical

"Seminoma is the most common malignant solid tumor in 14 to 44 year-old men"

Supports the testicular mass presentation and demographic of seminoma.

Cryptorchidism (Risk Factor) Cryptorchidism HP:0000028

Show evidence (2 references)

PMID:23423470 SUPPORT Human Clinical

"history of CO is associated with four-fold increased TGCT risk [RR = 4.1(95% CI = 3.6-4.7)]"

Comprehensive meta-analysis of case-control and cohort studies quantifies the cryptorchidism (CO) to testicular germ cell tumor (TGCT) association at RR 4.1; the same paper reports the association is stronger for seminoma histology.

PMID:23423470 SUPPORT Human Clinical

"these results also suggested a stronger association of CO with seminoma"

The same meta-analysis found the cryptorchidism association is stronger for seminoma histology than for non-seminoma, underscoring its particular relevance to seminoma.

Other 3

Germ Cell Neoplasia In Situ Germ cell neoplasia HP:0100728

Show evidence (1 reference)

PMID:29799399 SUPPORT Human Clinical

"Germ-cell neoplasia in situ (GCNIS) is accepted as the precursor of the testicular tumors"

Confirms GCNIS as the accepted preinvasive precursor lesion of testicular germ cell tumors, including seminoma.

Elevated Serum Beta-hCG Elevated circulating beta chorionic gonadotropin concentration HP:6000485

Show evidence (1 reference)

PMID:31275973 SUPPORT Human Clinical

"in pure seminomas 28%, 2.8%, 29.1%, and 30.3%"

In a contemporary cohort of 422 GCT patients, elevated beta-hCG (bHCG) was found in 28% of pure seminomas (the first value in the listed bHCG, AFP, LDH, bHCG-or-AFP frequencies), with near-absent AFP elevation (2.8%) as expected for pure seminoma.

Elevated Serum LDH Increased circulating lactate dehydrogenase concentration HP:0025435

Show evidence (1 reference)

PMID:31275973 SUPPORT Human Clinical

"in pure seminomas 28%, 2.8%, 29.1%, and 30.3%"

In the same 422-patient GCT cohort, LDH was elevated in 29.1% of pure seminomas (the third value in the listed bHCG, AFP, LDH, bHCG-or-AFP frequencies), and the authors note LDH elevation associates with higher stage and tumour burden.

🧬

Genetic Associations

3

KIT (Activating mutations and focal amplification; mutations enriched in seminoma)

Show evidence (1 reference)

DOI:10.3389/fonc.2023.1133363 SUPPORT Human Clinical

"Variants were also detected in genes such as KIT, KRAS, PDGFRA, EGFR, BRAF, RET, NRAS, PIK3CA, MET, and ERBB2, with some of them potentially targetable"

Identifies KIT among the recurrently mutated, potentially targetable driver genes in TGCT.

KRAS (Copy-number gain (via 12p) very frequent; activating mutations recurrent)

Show evidence (1 reference)

DOI:10.3389/fonc.2023.1133363 SUPPORT Human Clinical

"KRAS copy number gain was a very frequent event (80.4%) in TGCT and presented a worse prognosis compared with the group with no KRAS copy gain (10y-OS, 90% vs. 81.5%, p = 0.048)"

Documents frequency and prognostic impact of KRAS copy-number gain in TGCT.

Isochromosome 12p (Hallmark cytogenetic abnormality of TGCT; gain of 12p near-universal)

Show evidence (1 reference)

DOI:10.1038/s41467-024-53193-6 SUPPORT Human Clinical

"a comprehensive, high-resolution map of copy number alterations, structural variation, and key global genome features"

WGS catalogue of adult TGCTs documents the copy-number-dominated genome (including 12p gain) characteristic of seminoma.

💊

Medical Actions

6

Radical Inguinal Orchiectomy

Action: radical orchiectomy Ontology label: surgical procedure MAXO:0000004

Radical inguinal orchiectomy is the primary diagnostic and therapeutic procedure for a suspected testicular tumor, providing histologic diagnosis and pathologic staging. Trans-scrotal biopsy is contraindicated due to tumor-seeding risk.

Active Surveillance (Stage I)

Action: active surveillance Ontology label: supportive care MAXO:0000950

Surveillance is the preferred post-orchiectomy strategy for clinical stage I seminoma, since the majority of patients do not relapse; it spares a young survivor population the long-term toxicity of adjuvant therapy. Recurrence risk is generally ~15-20%, often within the first year, and salvage is highly effective. Serial serum miR-371a-3p improves relapse detection.

Show evidence (2 references)

PMID:37967143 SUPPORT Human Clinical

"258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques"

Describes the prospective stage I surveillance protocol with serial miR-371a-3p.

PMID:37967143 SUPPORT Human Clinical

"Thirty-nine patients recurred (15.1%), all with elevated M371 levels"

In the prospective stage I surveillance cohort, 15.1% of patients relapsed - consistent with the ~15-20% recurrence risk that makes surveillance viable - and every relapse was accompanied by elevated miR-371a-3p.

Single-Agent Carboplatin

Action: chemotherapy MAXO:0000647

Agent: carboplatin CHEBI:31355

Adjuvant single-agent carboplatin (1-2 cycles) is an option for stage I seminoma as an alternative to surveillance, exploiting the marked platinum sensitivity of seminoma while limiting toxicity relative to multi-agent regimens or radiotherapy.

BEP / EP Platinum Chemotherapy

Action: chemotherapy MAXO:0000647

Agent: cisplatin CHEBI:27899 etoposide CHEBI:4911 bleomycin CHEBI:22907

Cisplatin-based combination chemotherapy - BEP (bleomycin, etoposide, cisplatin) or EP (etoposide, cisplatin) - is the standard systemic therapy for metastatic/advanced seminoma, curing the great majority of patients owing to seminoma's intrinsic platinum sensitivity.

Show evidence (1 reference)

PMID:37891379 SUPPORT In Vitro

"metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients using cisplatin-based combination therapy"

Supports the high cure rate of cisplatin-based combination chemotherapy in metastatic TGCT.

Radiation Therapy

Action: Radiation Therapy NCIT:C15313

Seminoma is highly radiosensitive; adjuvant para-aortic radiotherapy was historically standard for stage I and is still an option for stage I and stage IIA/B disease, though it has largely been supplanted by surveillance or carboplatin in stage I to reduce the long-term risk of second malignancy and cardiovascular toxicity.

Retroperitoneal Lymph Node Dissection (RPLND)

Action: retroperitoneal lymph node dissection Ontology label: surgical procedure MAXO:0000004

RPLND has an evolving, selective role in seminoma, used for staging or for managing residual/limited retroperitoneal disease in chosen patients as an alternative to chemotherapy or radiotherapy.

🌍

Environmental Factors

2

Cryptorchidism

Undescended testis is the strongest established risk factor for testicular germ cell tumors including seminoma.

Testicular Dysgenesis Syndrome

Seminoma is considered part of the testicular dysgenesis syndrome spectrum (cryptorchidism, hypospadias, impaired spermatogenesis/infertility) linked to disrupted fetal testicular development.

🔬

Biochemical Markers

4

Alpha-Fetoprotein (AFP) (Not elevated in pure seminoma)

Beta-Human Chorionic Gonadotropin (beta-hCG) (Mildly elevated in a subset of pure seminomas)

Lactate Dehydrogenase (LDH) (Elevated proportional to tumor burden)

microRNA-371a-3p (miR-371a-3p) (Elevated in serum of patients with viable (non-teratomatous) germ cell tumor)

Show evidence (2 references)

PMID:37967143 SUPPORT Human Clinical

"area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%"

Prospective multicenter study showing high diagnostic performance of miR-371a-3p for relapse detection in clinical stage I testicular germ cell tumor surveillance.

DOI:10.3390/jcm13237448 SUPPORT Human Clinical

"miR371a-3p has been identified as a promising biomarker with sensitivity and specificity of approximately 90–92% and 84–86%, respectively"

Confirms the overall reported performance characteristics of miR-371a-3p in germ cell tumor patients.

{ }

Source YAML

click to show

name: Testicular Seminoma
creation_date: "2026-06-17T00:00:00Z"
description: >-
  Testicular seminoma is the most common pure histologic type of testicular germ cell
  tumor (TGCT) and the most common solid malignancy in men aged roughly 15-44 years.
  Classic (typical) seminoma arises from germ cell neoplasia in situ (GCNIS), a
  preinvasive lesion of arrested fetal gonocytes, and recapitulates a primordial germ
  cell gene-expression program (OCT4/POU5F1, SOX17, NANOG, TFAP2C). It is genomically
  dominated by copy-number change rather than point mutation, with near-universal gain
  of the short arm of chromosome 12 (isochromosome 12p) and recurrent KIT and KRAS
  alterations. Pure seminoma characteristically does not elevate alpha-fetoprotein (AFP);
  beta-hCG and LDH may be elevated in a subset. Seminoma is exquisitely radiosensitive
  and platinum-chemosensitive, with cure rates approaching 99% in early-stage and over
  80% in advanced disease. The morphologically and biologically distinct spermatocytic
  tumor (formerly spermatocytic seminoma) occurs in older men, is GCNIS-independent,
  lacks i(12p), and is almost always benign; it is retained here as a contrasting subtype
  to make the lump/split boundary explicit.
categories:
- Germ Cell Neoplasm
- Solid Tumor
- Urologic Cancer
parents:
- testicular germ cell tumor
- malignant testicular germ cell tumor
disease_term:
  preferred_term: testicular seminoma
  term:
    id: MONDO:0003669
    label: testicular seminoma
classifications:
  icdo_morphology:
    classification_value: Embryonal Neoplasm
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
has_subtypes:
- name: Classic Seminoma
  display_name: Classic (Typical) Seminoma
  description: >-
    Classic seminoma is the prototypical and by far most common form, accounting for the
    great majority of pure seminomas. It arises from GCNIS, occurs predominantly in men
    aged 15-44 with a peak around 35-39 years, and presents most often as clinical stage I
    disease. Histologically it shows sheets and nests of uniform polygonal cells with clear,
    glycogen-rich cytoplasm and central nuclei, separated by fibrous septa containing a
    characteristic lymphocytic infiltrate. It is GCNIS-derived, harbors i(12p), expresses
    the primordial-germ-cell/pluripotency program (OCT4, SOX17, NANOG, TFAP2C), and is
    highly radio- and chemosensitive.
  subtype_frequency: ">90% of pure seminomas"
  evidence:
  - reference: DOI:10.1038/s41467-023-44305-9
    reference_title: "Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seminoma is the most common malignant solid tumor in 14 to 44 year-old men
    explanation: >-
      Establishes classic seminoma as the most common solid malignancy in this age range.
- name: Spermatocytic Tumor
  display_name: Spermatocytic Tumor (formerly Spermatocytic Seminoma)
  description: >-
    Spermatocytic tumor is a rare, biologically distinct germ cell tumor that, despite the
    historical name, is NOT a variant of classic seminoma. It occurs almost exclusively in
    older men (typically >50 years), arises independently of GCNIS, lacks isochromosome 12p
    and the OCT4/pluripotency program, shows three cell populations (small, intermediate,
    large) without lymphocytic infiltrate, and is almost always benign with rare metastasis.
    It is included here only to make the lump/split decision explicit: it is split from the
    classic seminoma concept and is not managed with the seminoma radiotherapy/chemotherapy
    paradigm. Curated as a contrasting subtype rather than as a true sub-form of classic
    seminoma.
  subtype_frequency: "<1% of testicular germ cell tumors"
pathophysiology:
- name: Germ Cell Neoplasia In Situ (GCNIS)
  description: >-
    Classic seminoma arises from germ cell neoplasia in situ (GCNIS), a preinvasive lesion
    composed of transformed fetal gonocytes/primordial germ cells that failed to mature and
    remained dormant within the seminiferous tubules until pubertal hormonal stimulation.
    Unlike most cancers, TGCTs including seminoma are rarely driven by somatic point
    mutations; instead they reflect a failure to control the latent developmental potential
    of their fetal germ-cell-of-origin, with reprogramming toward a malignant primordial
    germ cell-like state.
  evidence:
  - reference: DOI:10.1038/s41467-024-53193-6
    reference_title: "Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      our findings provide valuable insights into the developmental and immune modulatory
      processes implicated in TGCT pathogenesis and progression
    explanation: >-
      WGS of adult TGCTs frames seminoma pathogenesis as a developmental/immune-modulatory
      process arising from the fetal germ cell lineage.
  - reference: DOI:10.1038/s41467-023-44305-9
    reference_title: "Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identify key gene expression programs share between seminoma and primordial germ
      cells, and further characterize the functions of TFAP2C in promoting tumor invasion
      and migration
    explanation: >-
      Single-cell multi-omics confirms the shared primordial germ cell program of seminoma
      and identifies TFAP2C as a driver of invasion, consistent with a GCNIS/gonocyte origin.
  cell_types:
  - preferred_term: primordial germ cell
    term:
      id: CL:0000670
      label: primordial germ cell
  biological_processes:
  - preferred_term: germ cell development
    modifier: ABNORMAL
    term:
      id: GO:0007281
      label: germ cell development
  locations:
  - preferred_term: seminiferous tubule
    term:
      id: UBERON:0001343
      label: seminiferous tubule of testis
  downstream:
  - target: Isochromosome 12p and Copy-Number-Driven Genome
    description: >-
      GCNIS progresses to invasive seminoma after acquiring chromosome 12p gain and
      additional copy-number alterations.
- name: Isochromosome 12p and Copy-Number-Driven Genome
  description: >-
    Seminoma genomes are dominated by chromosomal copy-number change rather than recurrent
    somatic point mutations. Gain of the short arm of chromosome 12 - most often as
    isochromosome 12p [i(12p)] - is the hallmark cytogenetic event, and whole-genome
    sequencing of adult TGCTs identifies recurrent arm-level gains spanning KRAS on 12p.
    The 12p region harbors KRAS, CCND2, and NANOG, supporting pluripotency and proliferation.
  evidence:
  - reference: DOI:10.3389/fonc.2023.1133363
    reference_title: "Somatic mutation detection and KRAS amplification in testicular germ cell tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KRAS copy number gain was a very frequent event (80.4%) in TGCT and presented a worse
      prognosis compared with the group with no KRAS copy gain (10y-OS, 90% vs. 81.5%, p = 0.048)
    explanation: >-
      Demonstrates the high frequency and prognostic relevance of KRAS (12p) copy-number gain
      in TGCT, consistent with i(12p) biology.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  - preferred_term: chromosome organization
    modifier: ABNORMAL
    term:
      id: GO:0051276
      label: chromosome organization
  downstream:
  - target: KIT and RAS-MAPK Signaling Activation
    description: >-
      12p-amplified KRAS and recurrent KIT amplification converge on RAS-MAPK signaling.
- name: KIT and RAS-MAPK Signaling Activation
  description: >-
    Activating alterations of KIT and KRAS are the principal recurrent driver events in
    seminoma. WGS of adult TGCTs identified focal KIT amplification in approximately 19% of
    cases, and KIT mutations are enriched in seminoma relative to non-seminoma. KIT (a
    receptor tyrosine kinase) and amplified/mutated KRAS activate the RAS-RAF-MEK-ERK (MAPK)
    cascade, driving germ cell survival and proliferation.
  evidence:
  - reference: DOI:10.1038/s41467-024-53193-6
    reference_title: "Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular germ cell tumours (TGCT), which comprise seminoma and non-seminoma subtypes,
      are the most common cancers in young men
    explanation: >-
      Anchors the WGS catalogue (which reports recurrent KIT amplification and 12p/KRAS gains)
      to seminoma and non-seminoma TGCT subtypes.
  - reference: DOI:10.3389/fonc.2023.1133363
    reference_title: "Somatic mutation detection and KRAS amplification in testicular germ cell tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variants were also detected in genes such as KIT, KRAS, PDGFRA, EGFR, BRAF, RET, NRAS,
      PIK3CA, MET, and ERBB2, with some of them potentially targetable
    explanation: >-
      Confirms recurrent KIT and KRAS variants among the actionable driver genes in TGCT.
  gene_products:
  - preferred_term: KIT receptor tyrosine kinase
    term:
      id: NCIT:C17328
      label: Mast/Stem Cell Growth Factor Receptor Kit
  biological_processes:
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  downstream:
  - target: Platinum and Radiation Sensitivity
    description: >-
      KIT/RAS-MAPK-driven proliferation underlies the high mitotic activity and limited DNA
      damage tolerance of seminoma cells, which is precisely what cisplatin-based chemotherapy
      and radiotherapy exploit to achieve the characteristically high cure rates.
- name: Immune-Infiltrated Microenvironment and HLA-Loss Immune Evasion
  description: >-
    Seminoma is characteristically heavily infiltrated by immune cells, with a shift from
    the macrophage-dominated normal testis toward a T-cell-, B-cell-, and dendritic-cell-rich
    microenvironment. CD4+ T cells predominate over CD8+ cells, and regulatory T (Treg) and
    follicular helper T (Tfh) cells are most abundant in seminoma. Single-cell/spatial
    studies localize immune subtypes with exhaustion features adjacent to the tumor.
    Whole-genome sequencing identifies human leukocyte antigen (HLA) loss as a
    seminoma-enriched mechanism of immune disruption, providing a route to immune evasion
    despite robust infiltration.
  evidence:
  - reference: DOI:10.1038/s41416-024-02669-9
    reference_title: "T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In most samples (96%), the CD4+ T cell frequency exceeded that of CD8+ cells, with
      decreasing numbers from central to peripheral tumor areas, and to tumor-free,
      contralateral testes. T cells including Treg and Tfh were most abundant in seminoma
      compared to mixed tumors and embryonal carcinoma
    explanation: >-
      Documents the CD4-predominant infiltrate and seminoma enrichment of Treg/Tfh subsets.
  - reference: DOI:10.1038/s41467-024-53193-6
    reference_title: "Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we present evidence that human leukocyte antigen loss is a more prevalent mechanism of
      immune disruption in seminomas
    explanation: >-
      WGS identifies HLA loss as a seminoma-enriched immune-evasion mechanism.
  - reference: DOI:10.1038/s41467-023-44305-9
    reference_title: "Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also identify 15 immune cell subtypes in TME, and find that subtypes with
      exhaustion features were located closer to the tumor region through combined spatial
      transcriptome analysis
    explanation: >-
      Spatial multi-omics shows exhaustion-featured immune subtypes localizing to the
      seminoma tumor region.
  - reference: DOI:10.1038/s41416-024-02669-9
    reference_title: "T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Profound changes in immune cell composition within TGCT, shifting from macrophages
      in normal testes to T cells plus B and dendritic cells in TGCT, were documented
    explanation: >-
      Directly documents the shift from a macrophage-dominated normal testis to a
      T-cell-, B-cell-, and dendritic-cell-rich microenvironment in TGCT.
  cell_types:
  - preferred_term: CD4-positive T cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  - preferred_term: regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: T cell activation
    modifier: INCREASED
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: antigen presentation via MHC class I
    modifier: DECREASED
    term:
      id: GO:0002474
      label: antigen processing and presentation of peptide antigen via MHC class I
- name: Platinum and Radiation Sensitivity
  description: >-
    Seminoma is exquisitely sensitive to both ionizing radiation and platinum-based
    chemotherapy. As with TGCTs broadly, this sensitivity reflects limited DNA repair
    capacity - notably reduced ERCC1-XPF that impairs repair of cisplatin interstrand
    crosslinks - combined with a strong propensity to undergo apoptosis. Because TGCTs
    including seminoma almost universally retain wild-type TP53, DNA-damaging therapy
    drives a robust p53-controlled apoptotic response through both the intrinsic
    mitochondrial pathway (high endogenous Bax and Noxa with low Bcl-2, Bax translocation
    to the mitochondrial membrane and cytochrome c release) and the extrinsic Fas/FasL
    death-receptor pathway, so that DNA-damaging therapy efficiently triggers tumor cell
    death. This underlies cure rates approaching 99% in early-stage and over 80% in
    advanced disease.
  evidence:
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      metastatic testicular germ cell tumors (TGCT) are cured in over 80% of patients
      using cisplatin-based combination therapy. Published data suggest that TGCTs are
      sensitive to cisplatin due to limited DNA repair and presumably also to a
      propensity to undergo apoptosis
    explanation: >-
      Establishes the dual basis (limited DNA repair plus apoptotic propensity) for the
      platinum sensitivity that seminoma shares with TGCTs.
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      both the death receptor and the mitochondrial apoptotic pathway become strongly
      activated in TTC following cisplatin treatment, explaining, together with attenuated
      DNA repair, their unique sensitivity toward platinum-based anticancer drugs
    explanation: >-
      In testis tumor cell lines, cisplatin activates both the extrinsic Fas/FasL
      death-receptor and the intrinsic mitochondrial apoptotic pathways, which together
      with attenuated DNA repair account for the exceptional platinum sensitivity.
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Almost all TGCT are characterized by wild-type p53
    explanation: >-
      Near-universal retention of wild-type TP53 is the basis for the intact p53-driven
      apoptotic response that renders seminoma and other TGCTs platinum-sensitive.
  - reference: DOI:10.3390/jcm13237448
    reference_title: "Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Testicular cancer is the most common cancer among young adult men and has favorable
      outcomes, with survival rates approaching 99% and over 80% for those with early and
      advanced stage disease, respectively
    explanation: >-
      Confirms the favorable survival outcomes attributable to seminoma treatment sensitivity.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: extrinsic apoptotic signaling via Fas/FasL
    modifier: INCREASED
    term:
      id: GO:0008625
      label: extrinsic apoptotic signaling pathway via death domain receptors
  - preferred_term: intrinsic (mitochondrial) apoptotic signaling
    modifier: INCREASED
    term:
      id: GO:0097193
      label: intrinsic apoptotic signaling pathway
  - preferred_term: nucleotide-excision repair
    modifier: DECREASED
    term:
      id: GO:0006289
      label: nucleotide-excision repair
phenotypes:
- category: Neoplastic
  name: Testicular Mass
  description: >-
    A painless (or mildly painful) unilateral testicular mass is the typical presenting
    feature. Seminoma is the most common malignant solid tumor in men roughly 14-44 years
    of age, with nearly 80% presenting at clinical stage I.
  evidence:
  - reference: DOI:10.1038/s41467-023-44305-9
    reference_title: "Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seminoma is the most common malignant solid tumor in 14 to 44 year-old men
    explanation: >-
      Supports the testicular mass presentation and demographic of seminoma.
  phenotype_term:
    preferred_term: Testicular neoplasm
    term:
      id: HP:0010788
      label: Testicular neoplasm
- category: Neoplastic
  name: Germ Cell Neoplasia In Situ
  diagnostic: true
  description: >-
    Adjacent germ cell neoplasia in situ (GCNIS) is found in nearly all postpubertal
    seminomas and represents the preinvasive precursor lesion.
  evidence:
  - reference: PMID:29799399
    reference_title: "Evaluation of germ-cell neoplasia in situ entity in testicular tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Germ-cell neoplasia in situ (GCNIS) is accepted as the precursor of
      the testicular tumors
    explanation: >-
      Confirms GCNIS as the accepted preinvasive precursor lesion of testicular germ
      cell tumors, including seminoma.
  phenotype_term:
    preferred_term: Germ cell neoplasia
    term:
      id: HP:0100728
      label: Germ cell neoplasia
- category: Laboratory
  name: Elevated Serum Beta-hCG
  description: >-
    Beta-human chorionic gonadotropin (beta-hCG) is mildly elevated in a minority of pure
    seminomas (commonly cited ~10-20%, with contemporary cohorts reporting up to ~28%),
    reflecting scattered syncytiotrophoblastic giant cells. Pure seminoma does NOT elevate
    alpha-fetoprotein (AFP); a raised AFP indicates non-seminomatous elements.
  evidence:
  - reference: PMID:31275973
    reference_title: "Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in pure seminomas 28%, 2.8%, 29.1%, and 30.3%
    explanation: >-
      In a contemporary cohort of 422 GCT patients, elevated beta-hCG (bHCG) was found in
      28% of pure seminomas (the first value in the listed bHCG, AFP, LDH, bHCG-or-AFP
      frequencies), with near-absent AFP elevation (2.8%) as expected for pure seminoma.
  phenotype_term:
    preferred_term: Elevated serum beta-hCG
    term:
      id: HP:6000485
      label: Elevated circulating beta chorionic gonadotropin concentration
- category: Laboratory
  name: Elevated Serum LDH
  description: >-
    Lactate dehydrogenase (LDH) is elevated in a substantial fraction of seminoma patients
    (estimates range ~29-60% depending on stage mix and assay threshold) and reflects tumor
    burden; LDHB maps to 12p.
  evidence:
  - reference: PMID:31275973
    reference_title: "Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in pure seminomas 28%, 2.8%, 29.1%, and 30.3%
    explanation: >-
      In the same 422-patient GCT cohort, LDH was elevated in 29.1% of pure seminomas (the
      third value in the listed bHCG, AFP, LDH, bHCG-or-AFP frequencies), and the authors
      note LDH elevation associates with higher stage and tumour burden.
  phenotype_term:
    preferred_term: Increased serum LDH
    term:
      id: HP:0025435
      label: Increased circulating lactate dehydrogenase concentration
- category: Clinical
  name: Cryptorchidism (Risk Factor)
  description: >-
    A history of cryptorchidism (undescended testis) is the strongest established risk
    factor for testicular germ cell tumors including seminoma, increasing risk several-fold;
    orchiopexy reduces but does not abolish the risk.
  evidence:
  - reference: PMID:23423470
    reference_title: "Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      history of CO is associated with four-fold increased TGCT risk [RR = 4.1(95% CI = 3.6-4.7)]
    explanation: >-
      Comprehensive meta-analysis of case-control and cohort studies quantifies the
      cryptorchidism (CO) to testicular germ cell tumor (TGCT) association at RR 4.1; the
      same paper reports the association is stronger for seminoma histology.
  - reference: PMID:23423470
    reference_title: "Cryptorchidism and testicular germ cell tumors: comprehensive meta-analysis reveals that association between these conditions diminished over time and is modified by clinical characteristics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      these results also suggested a stronger association of CO with seminoma
    explanation: >-
      The same meta-analysis found the cryptorchidism association is stronger for seminoma
      histology than for non-seminoma, underscoring its particular relevance to seminoma.
  phenotype_term:
    preferred_term: Cryptorchidism
    term:
      id: HP:0000028
      label: Cryptorchidism
biochemical:
- name: Alpha-Fetoprotein (AFP)
  presence: Not elevated in pure seminoma
  notes: >-
    Elevated AFP in the setting of a testicular mass implies non-seminomatous (yolk sac /
    embryonal) elements rather than pure seminoma.
- name: Beta-Human Chorionic Gonadotropin (beta-hCG)
  presence: Mildly elevated in a subset of pure seminomas
  notes: >-
    Attributable to syncytiotrophoblastic giant cells; useful for staging and monitoring.
- name: Lactate Dehydrogenase (LDH)
  presence: Elevated proportional to tumor burden
  notes: Non-specific; LDHB gene located on 12p.
- name: microRNA-371a-3p (miR-371a-3p)
  presence: Elevated in serum of patients with viable (non-teratomatous) germ cell tumor
  notes: >-
    Leading emerging biomarker for germ cell tumors, with reported overall sensitivity and
    specificity of approximately 90-92% and 84-86%; cannot detect teratoma. In stage I
    surveillance it detects relapse with very high accuracy.
  evidence:
  - reference: PMID:37967143
    reference_title: "Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%,
      positive predictive value 83%, negative predictive value 100%
    explanation: >-
      Prospective multicenter study showing high diagnostic performance of miR-371a-3p for
      relapse detection in clinical stage I testicular germ cell tumor surveillance.
  - reference: DOI:10.3390/jcm13237448
    reference_title: "Current and Evolving Biomarkers in the Diagnosis and Management of Testicular Germ Cell Tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      miR371a-3p has been identified as a promising biomarker with sensitivity and
      specificity of approximately 90–92% and 84–86%, respectively
    explanation: >-
      Confirms the overall reported performance characteristics of miR-371a-3p in germ cell
      tumor patients.
genetic:
- name: KIT
  association: Activating mutations and focal amplification; mutations enriched in seminoma
  features: Amplified in ~19% of TGCTs by WGS; activates RAS-MAPK and PI3K-AKT
  evidence:
  - reference: DOI:10.3389/fonc.2023.1133363
    reference_title: "Somatic mutation detection and KRAS amplification in testicular germ cell tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variants were also detected in genes such as KIT, KRAS, PDGFRA, EGFR, BRAF, RET, NRAS,
      PIK3CA, MET, and ERBB2, with some of them potentially targetable
    explanation: >-
      Identifies KIT among the recurrently mutated, potentially targetable driver genes in TGCT.
- name: KRAS
  association: Copy-number gain (via 12p) very frequent; activating mutations recurrent
  features: KRAS copy-number gain in ~80% of TGCT; associated with worse 10-year overall survival
  evidence:
  - reference: DOI:10.3389/fonc.2023.1133363
    reference_title: "Somatic mutation detection and KRAS amplification in testicular germ cell tumors"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      KRAS copy number gain was a very frequent event (80.4%) in TGCT and presented a worse
      prognosis compared with the group with no KRAS copy gain (10y-OS, 90% vs. 81.5%, p = 0.048)
    explanation: >-
      Documents frequency and prognostic impact of KRAS copy-number gain in TGCT.
- name: Isochromosome 12p
  association: Hallmark cytogenetic abnormality of TGCT; gain of 12p near-universal
  features: >-
    Whole-genome sequencing identifies recurrent arm-level gains spanning KRAS on 12p; the
    region also carries CCND2 and NANOG.
  notes: Characteristic of GCNIS-derived seminoma and non-seminoma.
  evidence:
  - reference: DOI:10.1038/s41467-024-53193-6
    reference_title: "Genomic landscape of adult testicular germ cell tumours in the 100,000 Genomes Project"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a comprehensive, high-resolution map of copy number alterations, structural variation,
      and key global genome features
    explanation: >-
      WGS catalogue of adult TGCTs documents the copy-number-dominated genome (including 12p
      gain) characteristic of seminoma.
environmental:
- name: Cryptorchidism
  description: >-
    Undescended testis is the strongest established risk factor for testicular germ cell
    tumors including seminoma.
  effect: Strong risk factor for seminoma development
- name: Testicular Dysgenesis Syndrome
  description: >-
    Seminoma is considered part of the testicular dysgenesis syndrome spectrum (cryptorchidism,
    hypospadias, impaired spermatogenesis/infertility) linked to disrupted fetal testicular
    development.
  effect: Shared developmental etiology with other components of the syndrome
treatments:
- name: Radical Inguinal Orchiectomy
  description: >-
    Radical inguinal orchiectomy is the primary diagnostic and therapeutic procedure for a
    suspected testicular tumor, providing histologic diagnosis and pathologic staging.
    Trans-scrotal biopsy is contraindicated due to tumor-seeding risk.
  treatment_term:
    preferred_term: radical orchiectomy
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Active Surveillance (Stage I)
  description: >-
    Surveillance is the preferred post-orchiectomy strategy for clinical stage I seminoma,
    since the majority of patients do not relapse; it spares a young survivor population the
    long-term toxicity of adjuvant therapy. Recurrence risk is generally ~15-20%, often within
    the first year, and salvage is highly effective. Serial serum miR-371a-3p improves relapse
    detection.
  evidence:
  - reference: PMID:37967143
    reference_title: "Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      258 patients with testicular CSI GCT were prospectively followed by
      surveillance for a median time of 18 months with serial measurements of serum
      M371 levels, in addition to standard diagnostic techniques
    explanation: >-
      Describes the prospective stage I surveillance protocol with serial miR-371a-3p.
  - reference: PMID:37967143
    reference_title: "Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirty-nine patients recurred (15.1%), all with elevated M371 levels
    explanation: >-
      In the prospective stage I surveillance cohort, 15.1% of patients relapsed -
      consistent with the ~15-20% recurrence risk that makes surveillance viable - and
      every relapse was accompanied by elevated miR-371a-3p.
  treatment_term:
    preferred_term: active surveillance
    term:
      id: MAXO:0000950
      label: supportive care
- name: Single-Agent Carboplatin
  description: >-
    Adjuvant single-agent carboplatin (1-2 cycles) is an option for stage I seminoma as an
    alternative to surveillance, exploiting the marked platinum sensitivity of seminoma while
    limiting toxicity relative to multi-agent regimens or radiotherapy.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: carboplatin
      term:
        id: CHEBI:31355
        label: carboplatin
- name: BEP / EP Platinum Chemotherapy
  description: >-
    Cisplatin-based combination chemotherapy - BEP (bleomycin, etoposide, cisplatin) or EP
    (etoposide, cisplatin) - is the standard systemic therapy for metastatic/advanced
    seminoma, curing the great majority of patients owing to seminoma's intrinsic platinum
    sensitivity.
  evidence:
  - reference: PMID:37891379
    reference_title: "Strong apoptotic response of testis tumor cells following cisplatin treatment."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      metastatic testicular germ cell tumors (TGCT) are cured in over 80% of
      patients using cisplatin-based combination therapy
    explanation: >-
      Supports the high cure rate of cisplatin-based combination chemotherapy in metastatic TGCT.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
    - preferred_term: etoposide
      term:
        id: CHEBI:4911
        label: etoposide
    - preferred_term: bleomycin
      term:
        id: CHEBI:22907
        label: bleomycin
- name: Radiation Therapy
  description: >-
    Seminoma is highly radiosensitive; adjuvant para-aortic radiotherapy was historically
    standard for stage I and is still an option for stage I and stage IIA/B disease, though
    it has largely been supplanted by surveillance or carboplatin in stage I to reduce the
    long-term risk of second malignancy and cardiovascular toxicity.
  treatment_term:
    preferred_term: Radiation Therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
- name: Retroperitoneal Lymph Node Dissection (RPLND)
  description: >-
    RPLND has an evolving, selective role in seminoma, used for staging or for managing
    residual/limited retroperitoneal disease in chosen patients as an alternative to
    chemotherapy or radiotherapy.
  treatment_term:
    preferred_term: retroperitoneal lymph node dissection
    term:
      id: MAXO:0000004
      label: surgical procedure
histopathology:
- name: Uniform Clear Cells in Sheets and Nests
  finding_term:
    preferred_term: Seminoma morphology
    term:
      id: NCIT:C9309
      label: Seminoma
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Sheets and nests of monotonous polygonal cells with abundant clear, glycogen-rich
    cytoplasm, distinct cell membranes, and central nuclei with prominent nucleoli,
    separated by delicate fibrous septa. Classic diagnostic morphology of seminoma.
- name: Lymphocytic Infiltrate in Fibrous Septa
  finding_term:
    preferred_term: chronic lymphocytic infiltrate
    term:
      id: NCIT:C35980
      label: Chronic Inflammatory Infiltrate
  frequency: FREQUENT
  description: >-
    A characteristic lymphocytic (predominantly T-cell) infiltrate within the fibrous septa
    is a hallmark of seminoma and reflects its immune-infiltrated microenvironment; a
    granulomatous reaction may also be seen.
  evidence:
  - reference: DOI:10.1038/s41416-024-02669-9
    reference_title: "T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immune cell infiltration is heterogeneous but common in testicular germ cell tumors
      (TGCT) and pre-invasive germ cell neoplasia in situ (GCNIS)
    explanation: >-
      Supports the common immune-cell infiltration that manifests histologically as the
      seminoma lymphocytic infiltrate.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 35 citations 2026-06-17T20:53:54.826652

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Testicular Seminoma
MONDO ID: (if available)
Category: Germ Cell Neoplasm

Research Objectives

Please provide a comprehensive research report on Testicular Seminoma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Testicular Seminoma — Disease Characteristics Research Report (2023–2024-focused)

Executive summary

Testicular seminoma is a common histologic subtype of testicular germ cell tumor (TGCT) that typically affects adolescents and young-to-middle-aged adult men, is often diagnosed at early stage, and has excellent cure rates with orchiectomy and risk-adapted adjuvant management. Key 2023–2024 advances include: (i) higher-resolution genomic maps from whole-genome sequencing (WGS) that emphasize recurrent 12p copy-number gains (including KRAS-region 12p) and immune-evasion mechanisms (HLA loss) with seminoma enrichment, (ii) single-cell/spatial atlases describing immune-cell heterogeneity and exhaustion features in seminoma microenvironments, and (iii) prospective clinical validation of serum microRNA-371a-3p (M371/miR-371a-3p) for relapse detection and for assessing viable tumor in specific clinical contexts, with performance characteristics that exceed traditional serum tumor markers. (leathlobhair2024genomiclandscapeof pages 1-2, thor2024mir371a3ppredictingviable pages 1-2, islam2024tcellsin pages 1-2, belge2024detectionofrecurrence pages 1-2)

1. Disease information

1.1 Definition and current understanding

Testicular germ cell tumors (TGCTs) are categorized into seminoma and nonseminomatous germ cell tumors (NSGCT). Seminoma is generally considered to arise from germ cell neoplasia in situ (GCNIS) and is characterized by a developmental-arrest phenotype resembling primordial germ cells/gonocytes. (lu2023singlecellmultiomicsanalysis pages 1-2, sykes2024currentandevolving pages 1-2)

Primary abstract quote (single-cell atlas, 2023): - “Seminoma is the most common malignant solid tumor in 14 to 44 year-old men.” (lu2023singlecellmultiomicsanalysis pages 1-2)

1.2 Key identifiers (ontology/coding)

The tool-accessible evidence retrieved for this report does not contain authoritative crosswalk tables for ICD-10/ICD-11, MeSH, OMIM, Orphanet, or a seminoma-specific MONDO identifier. Consequently, these identifiers cannot be populated with citation-grade support from the current evidence set.

MONDO (partial, available in OpenTargets context): OpenTargets returned MONDO_0003510 for “malignant testicular germ cell tumor” (broader than seminoma). (OpenTargets Search: testicular seminoma)

1.3 Synonyms / alternative names

The retrieved evidence uses primarily: - “testicular seminoma” (leathlobhair2024genomiclandscapeof pages 1-2) - “seminoma” (lu2023singlecellmultiomicsanalysis pages 1-2) - “seminomatous germ cell tumor” (fazekas2024earlydetectionand pages 4-7)

1.4 Evidence source type

The information below is derived from: - Aggregated disease-level resources (narrative review and guideline-style review; registry-like incidence statements) (sykes2024currentandevolving pages 1-2) - Primary human tumor studies (WGS; single-cell/spatial profiling; prospective biomarker validation cohorts) (belge2024detectionofrecurrence pages 1-2, lu2023singlecellmultiomicsanalysis pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2)

2. Etiology

2.1 Disease causal factors (mechanistic)

A central mechanistic concept is that TGCTs (including seminoma) reflect failure to control the latent developmental potential of the fetal germ cell lineage, followed by later progression under hormonal and genetic influences.

Primary abstract quote (WGS, 2024): - “Unlike most other cancers, TGCTs are rarely caused solely by somatic driver mutations, but arise from failure to control the latent developmental potential of their cell-of-origin, a foetal germ cell, resulting in its reprogramming.” (leathlobhair2024genomiclandscapeof pages 1-2)

2.2 Risk factors

The current evidence set includes disease-level epidemiologic and etiologic framing (GCNIS origin, immune infiltration) but is limited on seminoma-specific quantitative risk factor estimates.

Cryptorchidism is referenced as an established association with testicular cancer in recent literature retrieved, and a 2024 review notes a meta-analysis estimate of increased testicular cancer risk in congenital cryptorchidism (not seminoma-specific in the retrieved excerpt). (OpenTargets Search: testicular seminoma)

Neurodevelopmental disorders (NDDs): A nested case–control study reports a specific association with seminoma. - Abstract quote: “History of a neurodevelopmental disorder … was associated with an increased risk of seminoma (OR: 1.54; 1.09–2.19).” (OpenTargets Search: testicular seminoma)

Male infertility is discussed in retrieved review literature as part of a shared etiologic framework (testicular dysgenesis syndrome concept), but quantitative seminoma-specific effect sizes were not extractable from the provided evidence snippets in this run. (OpenTargets Search: testicular seminoma)

2.3 Protective factors

No protective genetic or environmental factors with extractable quantitative support were identified in the gathered evidence.

2.4 Gene–environment interactions

No explicit GxE interaction results were extractable from the current evidence set.

3. Phenotypes (clinical presentation)

3.1 Typical presentation and clinical features

Seminoma typically presents as a testicular mass; clinically it often has normal AFP (pure seminoma) with β-hCG elevations only in a subset.

From a clinical biomarkers review (2024): - AFP is not elevated in pure seminoma; β-hCG can be mildly elevated in ~10–20% of pure seminoma cases (reviewed evidence). (sykes2024currentandevolving pages 2-4, sykes2024currentandevolving pages 1-2)

From an additional clinical overview source in the evidence set: - Pure seminomas usually have normal AFP, while β-hCG can be elevated when trophoblastic elements are present. (fazekas2024earlydetectionand pages 4-7)

3.2 Phenotype characteristics (onset, frequency, progression)

Age range: commonly in young adult men; seminoma peak reported at 35–39 in one source. (fazekas2024earlydetectionand pages 4-7)
Stage distribution: “nearly 80% of seminoma patients present with clinical stage I.” (sykes2024currentandevolving pages 2-4)
Relapse risk after orchiectomy (stage I): generally 15–20% recurrence risk after orchiectomy, often within the first year. (sykes2024currentandevolving pages 4-5)

3.3 Suggested HPO terms (non-exhaustive, evidence-aligned)

Because the evidence set primarily addresses diagnosis/staging and biomarkers rather than symptom catalogs, HPO mapping here is conservative: - Testicular mass / testicular neoplasm phenotype concept (clinical presentation in evidence; no direct HPO IDs provided in sources). (sykes2024currentandevolving pages 4-5) - Abnormal serum β-hCG level (when elevated in seminoma subset). (fazekas2024earlydetectionand pages 10-13, sykes2024currentandevolving pages 2-4) - Abnormal serum LDH level. (fazekas2024earlydetectionand pages 10-13)

3.4 Quality-of-life impact

The evidence set emphasizes long-term toxicity/late effects as a major survivorship issue rather than QoL instrument scores.

4. Genetic / molecular information

4.1 Causal genes

Seminoma is not generally a single-gene Mendelian disorder; rather, it is a malignancy with recurrent somatic and copy-number alterations. In the accessible evidence: - KIT is repeatedly implicated (amplification in WGS cohort; mutations reported as seminoma-enriched in TGCT subtype analyses). (cabral2023somaticmutationdetection pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2)

4.2 Recurrent alterations and pathways (somatic/copy number)

12p copy-number gains (KRAS-region 12p): - WGS identified “chromosome arm-level gains spanning KRAS (12p)” among established recurrent CNAs. (leathlobhair2024genomiclandscapeof pages 1-2)

KIT focal amplification: - WGS found “amplifications involving KIT (4q12; 19% cases).” (leathlobhair2024genomiclandscapeof pages 1-2)

KRAS copy-number gain and prognosis (TGCT cohort): - In a 97-patient TGCT cohort, KRAS copy number gain occurred in 80.4% and was associated with worse 10-year OS (90% vs 81.5%, p=0.048). This is TGCT-wide and not seminoma-exclusive in the excerpt, but it is consistent with the prominence of 12p/KRAS-region alterations in TGCT biology. (cabral2023somaticmutationdetection pages 1-2)

4.3 Immune evasion / antigen presentation

HLA loss in seminoma: - WGS study: “human leukocyte antigen loss is a more prevalent mechanism of immune disruption in seminomas.” (leathlobhair2024genomiclandscapeof pages 1-2)

4.4 Epigenetic information

A 2023 review emphasizes that ncRNAs and epigenetic regulation are implicated in testicular cancers and that miRNA clusters (including 371–373) are candidates for liquid biopsy. (nunezcorona2023epigeneticfactorsand pages 2-3)

4.5 Suggested GO and CL terms (mechanism-aligned, non-exhaustive)

Based on evidence describing immune infiltration, exhaustion features, and developmental/primordial germ cell programs: - GO biological process (suggested): immune response modulation / antigen presentation processes (HLA loss context) (leathlobhair2024genomiclandscapeof pages 1-2) - CL cell types (suggested): CD4-positive T cell; regulatory T cell; follicular helper T cell; macrophage; dendritic cell (immune landscape evidence) (islam2024tcellsin pages 1-2)

5. Environmental information

The evidence set contains limited, seminoma-specific environmental exposure quantification. A 2024 epidemiologic review on cryptorchidism risk factors discusses maternal smoking and endocrine-disrupting chemical exposure as contributors to cryptorchidism risk, and cryptorchidism is associated with later testicular cancer risk, but causal environmental pathways to seminoma were not directly quantified in the evidence retrieved in this run. (OpenTargets Search: testicular seminoma)

6. Mechanism / pathophysiology

6.1 Causal chain (high-level, evidence-grounded)

Cell-of-origin / developmental arrest: seminoma reflects a germline developmental program resembling primordial germ cells and is considered GCNIS-derived. (lu2023singlecellmultiomicsanalysis pages 1-2)
Genomic evolution dominated by copy-number/structural changes: recurrent CNAs include 12p (KRAS-region) gains and KIT amplifications. (leathlobhair2024genomiclandscapeof pages 1-2)
Immune microenvironment and immune disruption: seminoma is characteristically immune-infiltrated; WGS suggests seminoma-enriched HLA loss as immune disruption; single-cell/spatial studies map immune subsets and exhaustion features near tumor. (islam2024tcellsin pages 1-2, lu2023singlecellmultiomicsanalysis pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2)
Clinical manifestations: testicular mass; early-stage predominance; marker-negative frequency for classic serum markers; excellent treatment sensitivity to radiotherapy and platinum chemotherapy. (fazekas2024earlydetectionand pages 10-13, sykes2024currentandevolving pages 4-5)

6.2 Immune system involvement (2023–2024 developments)

T-cell composition and rare subsets (2024): - Abstract quote: “Profound changes in immune cell composition within TGCT, shifting from macrophages in normal testes to T cells plus B and dendritic cells in TGCT, were documented. In most samples (96%), the CD4+ T cell frequency exceeded that of CD8+ cells… T cells including Treg and Tfh were most abundant in seminoma…” (islam2024tcellsin pages 1-2)

Single-cell/spatial multi-omics (2023): - Abstract quote: “We also identify 15 immune cell subtypes in TME, and find that subtypes with exhaustion features were located closer to the tumor region…” (lu2023singlecellmultiomicsanalysis pages 1-2)

7. Anatomical structures affected

Primary organ: testis (seminoma is a testicular germ cell tumor). (lu2023singlecellmultiomicsanalysis pages 1-2)
Metastatic pattern (general seminoma clinical pattern): predictable dissemination initially to the retroperitoneum before lungs/viscera is noted in a seminoma surgical management review (retrieved but not fully evidence-extracted in this run); therefore, detailed anatomic mapping is not citation-supported beyond general retroperitoneal involvement in the available sources. (thor2024mir371a3ppredictingviable pages 1-2)

Suggested UBERON terms (conceptual, evidence-aligned): testis; retroperitoneal lymph node region (metastatic/relapse surveillance contexts). (thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2)

8. Temporal development (natural history)

Onset: typically young adulthood; seminoma described in men 14–44 and peak at 35–39 in the retrieved evidence. (fazekas2024earlydetectionand pages 4-7, lu2023singlecellmultiomicsanalysis pages 1-2)
Stage at diagnosis: ~80% present with stage I (review evidence). (sykes2024currentandevolving pages 2-4)
Relapse timing (stage I): relapses often within the first year after orchiectomy (review evidence). (sykes2024currentandevolving pages 4-5)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

From a 2024 clinical biomarkers review: - U.S. annual incidence: 5.7 per 100,000; 9,760 estimated new U.S. cases in 2024. (sykes2024currentandevolving pages 1-2)

9.2 Inheritance

No Mendelian inheritance model applies. Familial aggregation and susceptibility loci are widely recognized in the field, but GWAS-locus details (e.g., KITLG/DMRT1 variants) were not extractable with citation-grade support from the evidence gathered in this run.

10. Diagnostics

10.1 Conventional serum tumor markers (limitations)

Traditional serum tumor markers (AFP, β-hCG, LDH) are limited in seminoma. - Abstract quote (2024 review): “Traditional serum tumor markers … are limited by overall low sensitivity (approximately 50%)…” (sykes2024currentandevolving pages 1-2) - Seminoma-specific marker sensitivity reported in reviewed data: AFP 2.3%, β-hCG 31%, LDH 28%, and 46% combined. (sykes2024currentandevolving pages 1-2) - Additional clinically relevant proportions: β-hCG “15%–20% in advanced disease” and LDH “40%–60%” in seminoma patients (as summarized in one clinical overview source). (fazekas2024earlydetectionand pages 10-13)

10.2 Emerging liquid biomarkers — miR-371a-3p (M371)

Relapse detection in stage I surveillance (prospective, 2024): - Cohort: 258 stage I TGCT patients, median follow-up 18 months. - Relapse: 39 (15.1%) recurrences; “all with elevated M371 levels.” - Performance: AUC 0.993; sensitivity 100%; specificity 96.3%; PPV 83%; NPV 100%. - Earlier relapse detection: 28%, but without significant median time gain.

Primary abstract quote: - “Thirty-nine patients recurred (15.1%), all with elevated M371 levels… area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%.” (belge2024detectionofrecurrence pages 1-2)

Viable tumor detection around RPLND (prospective, 2024): - In primary seminoma patients (n=24) undergoing primary RPLND, miR-371a-3p sensitivity 74% and specificity 100% (threshold >0.45 copies/µL), with decreased levels after surgery. (thor2024mir371a3ppredictingviable pages 1-2)

10.3 Imaging

For post-chemotherapy residual masses in seminoma, PET-CT is described as having high negative predictive value for masses >3 cm but low positive predictive value due to false positives. (sykes2024currentandevolving pages 4-5)

10.4 Pathology (histopathology/IHC)

Seminoma is described morphologically as immune-infiltrated and PGC-like in gene expression programs. - Gene-expression diagnostic markers: TFAP2C, SOX17, POU5F1/OCT4, NANOG are described as highly expressed and noted as “excellent diagnostic markers for seminoma and GCNIS.” (lu2023singlecellmultiomicsanalysis pages 1-2)

10.5 Differential diagnosis

The retrieved evidence does not provide a comprehensive differential diagnosis table (e.g., embryonal carcinoma, lymphoma, spermatocytic tumor) in extractable form.

11. Outcome / prognosis

TGCT prognosis is generally favorable: survival “approaching 99%” for early-stage disease and “exceeding 80%” for advanced-stage disease (review statement). (sykes2024currentandevolving pages 1-2)
A retrospective surveillance cohort cited in the biomarkers review reported 5-year survival 99% (stage I management context). (sykes2024currentandevolving pages 4-5)
A clinical overview states that “With current standard-of-care management 90–95% of testicular tumors are cured.” (fazekas2024earlydetectionand pages 10-13)

12. Treatment

12.1 Standard-of-care management (real-world implementation)

Stage I seminoma: - Radical orchiectomy is the foundational diagnostic/therapeutic step; post-orchiectomy options include surveillance (preferred), single-agent carboplatin (1–2 cycles), or radiotherapy. (sykes2024currentandevolving pages 4-5)

Rationale for surveillance/de-escalation: - A large fraction of stage I seminoma patients do not relapse; consequently, management aims to limit long-term toxicities in a young survivorship population. (sykes2024currentandevolving pages 4-5, sykes2024currentandevolving pages 1-2)

12.2 Long-term toxicities (key survivorship issue)

A 2024 review highlights long-term risks with radiation/chemotherapy; in the extracted evidence, radiation is associated with an “80% increased risk of death from secondary malignancy” (as presented in the review excerpt). (sykes2024currentandevolving pages 4-5)

12.3 Suggested MAXO terms (conceptual placeholders)

The evidence does not include MAXO IDs, but supports the following action concepts: - Radical inguinal orchiectomy; active surveillance; radiotherapy; platinum-based chemotherapy; retroperitoneal lymph node dissection (in selected contexts). (sykes2024currentandevolving pages 4-5, thor2024mir371a3ppredictingviable pages 1-2)

13. Prevention

No primary prevention interventions with evidence-supported efficacy were retrieved. Secondary prevention in practice is primarily risk-adapted surveillance and follow-up after orchiectomy. (sykes2024currentandevolving pages 4-5, belge2024detectionofrecurrence pages 1-2)

14. Other species / natural disease

No cross-species naturally occurring seminoma evidence was retrieved in the citation-grade set for this run.

15. Model organisms

The evidence set includes in vitro functional work referenced in a single-cell/multi-omics study (seminoma cell line usage), but detailed model organism cataloging was not extracted. (lu2023singlecellmultiomicsanalysis pages 1-2)

16. Recent developments & expert synthesis (2023–2024)

16.1 Genomics (2024 WGS at scale)

The Genomics England 100,000 Genomes Project WGS analysis provides a “high-resolution map” of CNAs/SVs and reports seminoma-enriched HLA loss as an immune-disruption mechanism, supporting immune-evasion hypotheses and potentially informing immunotherapy biomarker strategy. (leathlobhair2024genomiclandscapeof pages 1-2)

16.2 Tumor microenvironment atlases (2023–2024)

Single-cell/spatial profiling identifies immune heterogeneity, including exhaustion-featured immune states near tumor, and Br J Cancer 2024 highlights CD4-predominant infiltration and seminoma enrichment for rare Treg/Tfh subsets—collectively supporting a view of seminoma as an immune-infiltrated but potentially immunoregulatory/exhausted environment. (islam2024tcellsin pages 1-2, lu2023singlecellmultiomicsanalysis pages 1-2)

16.3 Liquid biopsy (miR-371a-3p) nearing implementation

Prospective validation shows M371’s high accuracy for relapse detection in stage I surveillance and high specificity in certain contexts (e.g., seminoma pre-chemotherapy RPLND cohort). Expert review consensus frames miR-371a-3p as a leading candidate biomarker with ~90–92% sensitivity and ~84–86% specificity overall in GCT patients, while noting limitations such as inability to detect teratoma. (thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2, sykes2024currentandevolving pages 1-2)

16.4 Ongoing trials / studies

A recruiting observational study to evaluate miRNA371 and outcomes in newly diagnosed germ cell tumors is identified as NCT07453082 (enrollment 100). (sykes2024currentandevolving pages 8-10)

Evidence summary table

The following table consolidates the key evidence-backed facts extracted in this run.

Domain	Key points	Best supporting sources	Publication info (year, journal)	URL
Identifiers/Definition	Testicular seminoma is a major histologic subtype of testicular germ cell tumors (TGCTs); TGCTs are divided into seminoma and nonseminomatous germ cell tumors. Seminoma comprises a little over half of testicular germ cell neoplasms, and pure seminoma accounts for ~40–50% of TGCTs in men aged 25–55. Seminoma is GCNIS-derived and typically has normal AFP, with possible β-hCG elevation in a subset. (fazekas2024earlydetectionand pages 4-7, sykes2024currentandevolving pages 1-2)	Fazekas 2024; Sykes et al. 2024 (fazekas2024earlydetectionand pages 4-7, sykes2024currentandevolving pages 1-2)	2024, ArXiv; 2024, Journal of Clinical Medicine	https://doi.org/10.14232/phd.12359; https://doi.org/10.3390/jcm13237448
Epidemiology	TGCTs most commonly affect men aged 20–39; U.S. incidence reported as 5.7/100,000 with an estimated 9,760 new U.S. cases in 2024. Seminoma peaks at age 35–39. Nearly 80% of seminoma patients present with clinical stage I disease. Long-term survival approaches ~99% for early-stage disease and >80% for advanced-stage disease. (fazekas2024earlydetectionand pages 4-7, sykes2024currentandevolving pages 2-4, sykes2024currentandevolving pages 1-2)	Fazekas 2024; Sykes et al. 2024 (fazekas2024earlydetectionand pages 4-7, sykes2024currentandevolving pages 2-4, sykes2024currentandevolving pages 1-2)	2024, ArXiv; 2024, Journal of Clinical Medicine	https://doi.org/10.14232/phd.12359; https://doi.org/10.3390/jcm13237448
Etiology/Risk	TGCTs arise from GCNIS/gonocyte precursor cells that remain senescent until puberty and then progress under hormonal and genetic influences; microenvironment interaction is implicated. Cryptorchidism is a strong risk factor: a 2024 review cites a meta-analysis estimating a fourfold increased testicular cancer risk in boys with congenital cryptorchidism. Maternal smoking in pregnancy was not associated with higher testicular cancer risk overall in meta-analysis and showed a lower, non-significant seminoma estimate (RR 0.79, 95% CI 0.59–1.04). Male infertility is also a risk factor in contemporary review literature. (cabral2023somaticmutationdetection pages 1-2)	Cabral et al. 2023; supporting recent risk reviews/search results summarized in retrieved evidence (cabral2023somaticmutationdetection pages 1-2)	2023, Frontiers in Oncology	https://doi.org/10.3389/fonc.2023.1133363
Molecular/Pathophysiology	Whole-genome sequencing identified recurrent chromosome arm-level gains spanning KRAS on 12p, consistent with 12p gain/i(12p)-type biology, and focal KIT amplifications (~19% of cases). Seminoma-relevant mutations/alterations across TGCT datasets include KIT, KRAS, NRAS, and PIK3CA; KRAS copy number gain was very frequent in one TGCT cohort (80.4%) and associated with worse 10-year OS (90% vs 81.5%, p=0.048). WGS also provided evidence that HLA loss is a more prevalent immune-disruption mechanism in seminomas. (cabral2023somaticmutationdetection pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2, OpenTargets Search: testicular seminoma)	Cabral et al. 2023; Leathlobhair et al. 2024; Open Targets disease-target association context (cabral2023somaticmutationdetection pages 1-2, leathlobhair2024genomiclandscapeof pages 1-2, OpenTargets Search: testicular seminoma)	2023, Frontiers in Oncology; 2024, Nature Communications	https://doi.org/10.3389/fonc.2023.1133363; https://doi.org/10.1038/s41467-024-53193-6
Immune microenvironment	Seminoma histology is typically infiltrated by T lymphocytes and macrophages/dendritic cells. Recent profiling shows a shift from macrophage-dominant normal testis to T-cell-, B-cell-, and dendritic-cell-rich TGCT microenvironments. CD4+ T cells exceeded CD8+ in 96% of samples; densities decreased from tumor center to periphery. Rare Treg and Tfh subsets were identified and were most abundant in seminoma relative to mixed tumors and embryonal carcinoma. Single-cell/spatial multi-omics identified 15 immune cell subtypes and localized exhaustion-featured subtypes closer to tumor regions. (fazekas2024earlydetectionand pages 4-7, islam2024tcellsin pages 1-2)	Fazekas 2024; Islam et al. 2024; Lu et al. 2023 as summarized in gathered evidence (fazekas2024earlydetectionand pages 4-7, islam2024tcellsin pages 1-2)	2024, ArXiv; 2024, British Journal of Cancer	https://doi.org/10.14232/phd.12359; https://doi.org/10.1038/s41416-024-02669-9
Diagnostics/biomarkers	Conventional serum tumor markers are weak in pure seminoma: AFP is not elevated; β-hCG is mildly elevated in ~10–20% of pure seminoma and ~15–20% in advanced disease; LDH is elevated in ~40–60%. Reported seminoma sensitivities were AFP 2.3%, β-hCG 31%, LDH 28%, and 46% combined. miR-371a-3p is the leading emerging biomarker: reported overall sensitivity ~90–92% and specificity ~84–86% for TGCTs; in surveillance of stage I TGCT, relapse detection showed AUC 0.993, sensitivity 100%, specificity 96.3%, PPV 83%, NPV 100%; in prechemotherapy primary seminoma undergoing RPLND, sensitivity was 74% and specificity 100%. PET-CT has high negative predictive value for post-chemotherapy seminoma residual masses >3 cm but low positive predictive value because of false positives. (fazekas2024earlydetectionand pages 10-13, sykes2024currentandevolving pages 2-4, sykes2024currentandevolving pages 4-5, sykes2024currentandevolving pages 1-2, thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2)	Sykes et al. 2024; Thor et al. 2024; Belge et al. 2024; Fazekas 2024 (fazekas2024earlydetectionand pages 10-13, sykes2024currentandevolving pages 2-4, sykes2024currentandevolving pages 4-5, sykes2024currentandevolving pages 1-2, thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2)	2024, Journal of Clinical Medicine; 2024, Journal of Urology; 2024, Clinical Cancer Research; 2024, ArXiv	https://doi.org/10.3390/jcm13237448; https://doi.org/10.1097/ju.0000000000004164; https://doi.org/10.1158/1078-0432.ccr-23-0730; https://doi.org/10.14232/phd.12359
Treatment/outcomes	Radical inguinal orchiectomy is the main diagnostic and therapeutic procedure for localized seminoma. Surveillance is preferred for stage I because ~80–85% will not relapse after orchiectomy alone; recurrence risk is generally 15–20%, often within the first year. Alternative adjuvant options are single-agent carboplatin (1–2 cycles) or radiotherapy. A retrospective surveillance cohort reported 5-year survival of 99%. Seminoma is highly sensitive to radiotherapy and platinum chemotherapy; for stage IIA/IIB, RT or 3 cycles BEP / 4 cycles EP are established. Long-term toxicity is important, including cardiac toxicity, secondary malignancies, and an 80% increased risk of death from secondary malignancy associated with radiation in cited review evidence. (fazekas2024earlydetectionand pages 4-7, sykes2024currentandevolving pages 4-5)	Fazekas 2024; Sykes et al. 2024; Passarelli et al. 2024 identified in search results (fazekas2024earlydetectionand pages 4-7, sykes2024currentandevolving pages 4-5)	2024, ArXiv; 2024, Journal of Clinical Medicine	https://doi.org/10.14232/phd.12359; https://doi.org/10.3390/jcm13237448
Trials	Current biomarker implementation studies include a listed miR-371 trial for seminoma and NSGCT across stages (trial size note 350 in review evidence) and the SWENOTECA-MIR prospective multicenter study evaluating miR-371a-3p around RPLND. A recruiting observational study is registered as “A Prospective Study to Evaluate miRNA371 and Outcomes in Patients With Newly Diagnosed Germ Cell Tumors” (NCT07453082; enrollment 100). (sykes2024currentandevolving pages 8-10, thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2)	Sykes et al. 2024; Thor et al. 2024; ClinicalTrials retrieval context (sykes2024currentandevolving pages 8-10, thor2024mir371a3ppredictingviable pages 1-2, belge2024detectionofrecurrence pages 1-2)	2024, Journal of Clinical Medicine; 2024, Journal of Urology; ClinicalTrials.gov record	https://doi.org/10.3390/jcm13237448; https://doi.org/10.1097/ju.0000000000004164

Table: This table condenses the strongest evidence gathered on testicular seminoma across definition, epidemiology, biology, diagnostics, treatment, and active trials. It is designed as a quick-reference artifact using only facts supported by the cited context IDs.

Key limitations of this report (evidence availability constraints)

Ontology identifiers (ICD, MeSH, Orphanet, OMIM, MONDO for seminoma) were not available in the retrieved citation-grade evidence. Only a broader TGCT MONDO term appeared in OpenTargets output. (OpenTargets Search: testicular seminoma)
Seminoma-specific environmental risk quantification (beyond association framing and the NDD OR from one study) was limited in the gathered evidence. (OpenTargets Search: testicular seminoma)
GWAS susceptibility loci and germline variant details were not extractable with citation support from the texts retrieved in this run.

References (URLs and publication dates)

Lu X et al. Nature Communications (Accepted 2023-12-07; DOI page indicates 2023 publication). https://doi.org/10.1038/s41467-023-44305-9 (lu2023singlecellmultiomicsanalysis pages 1-2)
Ní Leathlobhair M et al. Nature Communications (Accepted 2024-10-03). https://doi.org/10.1038/s41467-024-53193-6 (leathlobhair2024genomiclandscapeof pages 1-2)
Islam R et al. British Journal of Cancer (Published online 2024-04-22). https://doi.org/10.1038/s41416-024-02669-9 (islam2024tcellsin pages 1-2)
Belge G et al. Clinical Cancer Research (2024-11; DOI). https://doi.org/10.1158/1078-0432.CCR-23-0730 (belge2024detectionofrecurrence pages 1-2)
Thor A et al. Journal of Urology (2024-11; DOI). https://doi.org/10.1097/JU.0000000000004164 (thor2024mir371a3ppredictingviable pages 1-2)
Sykes J et al. Journal of Clinical Medicine (Published 2024-12-06). https://doi.org/10.3390/jcm13237448 (sykes2024currentandevolving pages 1-2)
Fazekas F. ArXiv / thesis deposit (2024; DOI). https://doi.org/10.14232/phd.12359 (fazekas2024earlydetectionand pages 4-7)
Cabral ERM et al. Frontiers in Oncology (2023-03; DOI). https://doi.org/10.3389/fonc.2023.1133363 (cabral2023somaticmutationdetection pages 1-2)

References

(leathlobhair2024genomiclandscapeof pages 1-2): Máire Ní Leathlobhair, A. Frangou, B. Kinnersley, A. Cornish, D. Chubb, E. Lakatos, P. Arumugam, Andreas J. Gruber, P. Law, Avraam Tapinos, G. M. Jakobsdottir, I. Peneva, A. Sahli, Evie M Smyth, R. Ball, R. Sylva, K. Benes, D. Stark, Robin J Young, Alexander T J Lee, Vincent Wolverson, R. Houlston, A. Sosinsky, A. Protheroe, Matthew J. Murray, D. Wedge, C. Verrill, and Máire Anna Ben Alex J. Daniel Richard Y. Rushan Ksenija Ní Leathlobhair Frangou Kinnersley Cornish Chubb B. Genomic landscape of adult testicular germ cell tumours in the 100,000 genomes project. Nature Communications, Oct 2024. URL: https://doi.org/10.1038/s41467-024-53193-6, doi:10.1038/s41467-024-53193-6. This article has 17 citations and is from a highest quality peer-reviewed journal.
(thor2024mir371a3ppredictingviable pages 1-2): Anna Thor, Mette Pernille Myklebust, Anna Grenabo Bergdahl, Per-Olof Lundgren, Viktor Skokic, Bjarte Almås, Hege Sagstuen Haugnes, Torgrim Tandstad, Olof Akre, Gabriella Cohn-Cedermark, Olav Dahl, and Anders Kjellman. Mir-371a-3p predicting viable tumor in patients undergoing retroperitoneal lymph node dissection for metastatic testicular cancer: the swenoteca-mir study. Nov 2024. URL: https://doi.org/10.1097/ju.0000000000004164, doi:10.1097/ju.0000000000004164. This article has 9 citations and is from a domain leading peer-reviewed journal.
(islam2024tcellsin pages 1-2): Rashidul Islam, Jannis Heyer, Miriam Figura, Xiaoyan Wang, Xichen Nie, Benedict Nathaniel, Sivanjah Indumathy, Katja Hartmann, Christiane Pleuger, Monika Fijak, Sabine Kliesch, Florian Dittmar, Adrian Pilatz, Florian Wagenlehner, Mark Hedger, Bruce Loveland, James H. Hotaling, Jingtao Guo, Kate Loveland, Hans-Christian Schuppe, and Daniela Fietz. T cells in testicular germ cell tumors: new evidence of fundamental contributions by rare subsets. British Journal of Cancer, 130:1893-1903, Sep 2024. URL: https://doi.org/10.1038/s41416-024-02669-9, doi:10.1038/s41416-024-02669-9. This article has 22 citations and is from a domain leading peer-reviewed journal.
(belge2024detectionofrecurrence pages 1-2): Gazanfer Belge, Cansu Dumlupinar, Tim Nestler, Markus Klemke, Peter Törzsök, Emanuela Trenti, Renate Pichler, Wolfgang Loidl, Yue Che, Andreas Hiester, Cord Matthies, Martin Pichler, Pia Paffenholz, Luis Kluth, Mike Wenzel, Jörg Sommer, Julia Heinzelbecker, Philipp Schriefer, Alexander Winter, Friedemann Zengerling, Mario Wolfgang Kramer, Marie Lengert, Jana Frey, Axel Heidenreich, Christian Wülfing, Arlo Radtke, and Klaus-Peter Dieckmann. Detection of recurrence through microrna-371a-3p serum levels in a follow-up of stage i testicular germ cell tumors in the drks-00019223 study. Clinical Cancer Research, 30:404-412, Nov 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-0730, doi:10.1158/1078-0432.ccr-23-0730. This article has 37 citations and is from a highest quality peer-reviewed journal.
(lu2023singlecellmultiomicsanalysis pages 1-2): Xiaojian Lu, Yanwei Luo, Xichen Nie, Bailing Zhang, Xiaoyan Wang, Ran Li, Guangmin Liu, Qianyin Zhou, Zhizhong Liu, Liqing Fan, James M. Hotaling, Zhe Zhang, Hao Bo, and Jingtao Guo. Single-cell multi-omics analysis of human testicular germ cell tumor reveals its molecular features and microenvironment. Nature Communications, Dec 2023. URL: https://doi.org/10.1038/s41467-023-44305-9, doi:10.1038/s41467-023-44305-9. This article has 37 citations and is from a highest quality peer-reviewed journal.
(sykes2024currentandevolving pages 1-2): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.
(OpenTargets Search: testicular seminoma): Open Targets Query (testicular seminoma, 31 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(fazekas2024earlydetectionand pages 4-7): Fruzsina Fazekas. Early detection and complex treatment of metastatic testicular germ cell cancer. ArXiv, 2024. URL: https://doi.org/10.14232/phd.12359, doi:10.14232/phd.12359. This article has 1 citations.
(sykes2024currentandevolving pages 2-4): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.
(sykes2024currentandevolving pages 4-5): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.
(fazekas2024earlydetectionand pages 10-13): Fruzsina Fazekas. Early detection and complex treatment of metastatic testicular germ cell cancer. ArXiv, 2024. URL: https://doi.org/10.14232/phd.12359, doi:10.14232/phd.12359. This article has 1 citations.
(cabral2023somaticmutationdetection pages 1-2): Eduardo R. M. Cabral, Marilia F. Pacanhella, Andre V. H. Lengert, Mariana B. dos Reis, Leticia F. Leal, Marcos A. de Lima, Aline L. V. da Silva, Icaro A. Pinto, Rui M. Reis, Mariana T. Pinto, and Flavio M. Cárcano. Somatic mutation detection and kras amplification in testicular germ cell tumors. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1133363, doi:10.3389/fonc.2023.1133363. This article has 12 citations.
(nunezcorona2023epigeneticfactorsand pages 2-3): David Nuñez-Corona, Estefania Contreras-Sanzón, Jonathan Puente-Rivera, Rodrigo Arreola, Minerva Camacho-Nuez, José Cruz Santiago, Edgar Antonio Estrella-Parra, Julio César Torres-Romero, César López-Camarillo, and María Elizbeth Alvarez-Sánchez. Epigenetic factors and ncrnas in testicular cancer. International Journal of Molecular Sciences, 24:12194, Jul 2023. URL: https://doi.org/10.3390/ijms241512194, doi:10.3390/ijms241512194. This article has 14 citations.
(sykes2024currentandevolving pages 8-10): Jennifer Sykes, Alain Kaldany, and Thomas L. Jang. Current and evolving biomarkers in the diagnosis and management of testicular germ cell tumors. Journal of Clinical Medicine, 13:7448, Dec 2024. URL: https://doi.org/10.3390/jcm13237448, doi:10.3390/jcm13237448. This article has 19 citations.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Source YAML

References & Deep Research

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Testicular Seminoma — Disease Characteristics Research Report (2023–2024-focused)

Executive summary

1. Disease information

1.1 Definition and current understanding

1.2 Key identifiers (ontology/coding)

1.3 Synonyms / alternative names

1.4 Evidence source type

2. Etiology

2.1 Disease causal factors (mechanistic)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical presentation)

3.1 Typical presentation and clinical features

3.2 Phenotype characteristics (onset, frequency, progression)

3.3 Suggested HPO terms (non-exhaustive, evidence-aligned)

3.4 Quality-of-life impact

4. Genetic / molecular information

4.1 Causal genes

4.2 Recurrent alterations and pathways (somatic/copy number)

4.3 Immune evasion / antigen presentation

4.4 Epigenetic information

4.5 Suggested GO and CL terms (mechanism-aligned, non-exhaustive)

5. Environmental information

6. Mechanism / pathophysiology

6.1 Causal chain (high-level, evidence-grounded)

6.2 Immune system involvement (2023–2024 developments)

7. Anatomical structures affected

8. Temporal development (natural history)

9. Inheritance and population

9.1 Epidemiology (recent statistics)

9.2 Inheritance

10. Diagnostics

10.1 Conventional serum tumor markers (limitations)

10.2 Emerging liquid biomarkers — miR-371a-3p (M371)

10.3 Imaging

10.4 Pathology (histopathology/IHC)

10.5 Differential diagnosis

11. Outcome / prognosis

12. Treatment

12.1 Standard-of-care management (real-world implementation)

12.2 Long-term toxicities (key survivorship issue)

12.3 Suggested MAXO terms (conceptual placeholders)

13. Prevention

14. Other species / natural disease